Fairfax, VANCT06905197Now EnrollingIRB Ready

Non Small Cell Lung Cancer Clinical Trial in Fairfax, VA

Access cutting-edge non small cell lung cancer treatment through this clinical trial at a research site in Fairfax. Study-provided care at no cost to qualified participants.

Sponsored by Dizal Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Fairfax location

Preparing your pre-screening questions…

Expert Care in Fairfax

Access non small cell lung cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related non small cell lung cancer treatment provided free

Apply for This Fairfax Location

Check if you qualify for this non small cell lung cancer clinical trial in Fairfax, VA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fairfax

    Convenient for VA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fairfax site if eligible
  4. 4Begin participation

About This Non Small Cell Lung Cancer Study in Fairfax

This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.

Sponsor: Dizal Pharmaceuticals

Who Can Participate

Inclusion Criteria

Patients must be able to provide documented informed consent.
Aged ≥ 18 years.
Histologically or cytologically confirmed diagnosis of NSCLC, locally advanced or metastatic, not suitable for curative therapy.
Documentation of EGFR mutations from a local CLIA-certified laboratory (or equivalent). For Part A monotherapy cohorts and all cohorts of Part B, EGFR sensitizing mutations (Exon19del and/or L858R) are required.
Provide adequate amount of pretreatment tumor samples collected after disease progression on the last EGFR TKI treatment. (previously treated patients) or before study treatment (treatment naïve patients).
Part A: Failed (progressed or are intolerant) from at least 1 prior EGFR TKI regimen. Cohort A of Part B: Failed 1 prior third-generation EGFR TKI regimen. Cohorts B of Part B: Patients who are treatment naïve.
ECOG 0 or 1 with predicted life expectancy ≥ 12 weeks.
Patients with brain metastases must have a stable BM status.
Measurable disease per RECIST 1.1.
Adequate hematopoietic and other organ system functions.
Male Patients with female partners of childbearing potential should use barrier contraceptives and refrain from donating sperm during their participation in this study and for 3 months following the last dose of the study drug.

Exclusion Criteria

Carry other EGFR alterations than T790M and C797X, including but not limited to uncommon EGFR mutations (G719X, S768I, L861Q, exon 20 insertions mutations, etc.)(Part B).
NSCLC with mixed small cell lung cancer (SCLC) or NSCLC with histologic SCLC transformation.
Prior treatment with any of the following: 1)Immunotherapy or other antibody therapy within 4 weeks prior to the first administration; 2)Any cytotoxic chemotherapy, investigational drugs or other anticancer drugs from a previous treatment regimen or clinical study within 14 days prior to the first administration; 3)Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose, radiation to more than 30% of the bone marrow or with a wide field of radiation within 28 days before screening; 4)Currently receiving or unable to stop drug or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 (CYP)3A4. A washout period of at least 2 weeks for strong inhibitors and 3 weeks for strong inducers is required prior to the first study drug administration; 5)currently receiving or unable to stop drugs known to be CYP3A4 sensitive substrate with a narrow therapeutic index. A washout period of at least 14 days is required prior to the first study drug administration; 6)currently receiving or unable to stop drugs known to be proton pump inhibitors. A washout period of at least 7 days is required prior to the first study drug administration; 7)major surgery within 4 weeks of the first administration of DZD6008 or anticipated during the study period.
Any unresolved toxicities from prior anti-cancer therapy greater than CTCAE Grade 1.
Spinal cord compression or leptomeningeal metastasis.
Patients with any other malignancy within 2 years of the first administration of study drug.
Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses as judged by investigator.
Patients with active infection, including but not limited to HBV, HCV, HIV and active infection of COVID-19.
Resting QTcF \> 470 msec; Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG;Any factors that increase the risk of QTc prolongation.
Past medical history of ILD or active ILD.
Diseases which would preclude adequate absorption of DZD6008.
Received a live vaccine within 2 weeks before the first administration of DZD6008.
Women who are pregnant or breastfeeding.
Hypersensitivity to active or inactive excipients of DZD6008 or sunvozertinib.
Involvement in the planning and conduct of the study.
Judgment by the investigator that the patient is unlikely to comply with study procedures

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fairfax?

Yes, this clinical trial (NCT06905197) has an active research site in Fairfax, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non Small Cell Lung Cancer Treatment Options in Fairfax, VA

If you're searching for non small cell lung cancer treatment options in Fairfax, VA, this clinical trial (NCT06905197) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fairfax research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non small cell lung cancer clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Fairfax, VA

See all lung cancer clinical trials recruiting in Fairfax — not just this study.

Browse Lung Cancer Trials in Fairfax →

Browse More Trials by Condition

Lung Cancer TrialsLeukemia TrialsSmall Cell Lung Cancer TrialsSpinal Muscular Atrophy TrialsAll Conditions →

Ready to Join in Fairfax?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fairfax, VA